TenNor Therapeutics (Suzhou) Limited (HKG:6872)

Market Cap	3.79B
Revenue (ttm)	n/a
Net Income	-160.84M
EPS	-3.82
Shares Out	52.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,200
Open	70.20
Previous Close	71.50
Day's Range	70.10 - 73.50
52-Week Range	62.25 - 287.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About HKG:6872

TenNor Therapeutics (Suzhou) Limited engages in discovery, development and commercialization of differentiated therapies for diseases associated with bacterial infections and bacterial metabolism. The company offers drug production and medical research and experimental development, with a pipeline of products such as Rifasutenizole (oral) for treatment of Helicobacter pylori infection, bacterial vaginosis, difficile infection; TNP-1232 for treatment of Helicobacter pylori infection; Rifasutenizole (injectable) for acute bacterial skin and skin ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 56
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6872

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error